Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-864-4 | CAS number: 2921-88-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Objective of study:
- metabolism
- toxicokinetics
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- Deviations:
- no
- GLP compliance:
- yes
- Specific details on test material used for the study:
- Substance ID: Chlorpyrifos
Lot#: AGR 200341
Purity: 99.9%
Radiolabelled substance ID: 14C-labelled chlorpyrifos
Inventory#: 541
Radiochemical purity: >99%
Specific activity: 15.78 (45 µCi/mg) - Radiolabelling:
- yes
- Species:
- rat
- Strain:
- other: CDF Fischer 344
- Details on species / strain selection:
- Rats were used because these are the preferred species for metabolism studies. The Fischer rat was selected because it is available from a reliable supplier, and it is the strain used in recent studies connucted on test substance in test facility.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, kingston, Newyork
- Age at study initiation: Not specified
- Weight at study initiation: Males: 173-250 g; Females: 128-170 g
- Housing: Animals were housed in pairs in suspended stainless steel cages with fronts and floors constructed of wire mesh. Cage board was placed under these cages and changed as required to control odor and maintain a clean environment.
- Diet: certified rodent chow (Ralston Purina #5002) ad libitum
- Water: Municipal tap water ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
The animals were housed in rooms designed to maintain adequate environmental conditions concerning temperature, humidity, air changes, and lighting for the species under test. - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Dose solutions containing 14C-labelled test substance: The 0.5 mg/kg dose solution was prepared by dissolving sufficient 14C-labeled test substance in USP corn oil to produce a solution containing approximately 0.27 mg test substance and 12 µCi/g of corn oil. The 25 mg/kg dose solution was prepared by dissolving sufficient analytical grade and 14C-labelled test substance in USP corn oil to produce a solution containing approximately 13.6 mg test substance and 12 µCi/g of corn oil. Concentrations of test substance and radioactivity in these solutions were determined by HPLC and 14C-analysis. These solutions were administered by gavage at a rate of 2 ml/kg of body weight using a syringe and stainless steel feeding needle. The quantity of dose solution actually administered was determined by weighing the syringe prior to and following administration of the dose.
Dose solution containing no radiolabelled test substance: The dose solution administered for 15 consecutive days was prepared by dissolving sufficient analytical grade chlorpyrifos in USP corn oil to produce a
solution containing about 0.27 mg test substance per g of corn oil. The concentration of test substance in this solution was determined to be 0.313 mg test substance/g when analyzed by HPLC. The concentration of test substance in a similarily prepared solution did not change when stored for up to two months at room temperature. This solution was administered by gavage at a rate of 2 ml/kg of body weight using a syringe and stainless steel feeding needle. The volume of dose solution administered was based on the animal's body weight taken at 3 to 4 day intervals. - Duration and frequency of treatment / exposure:
- Radiolabelled test substance: Single dose
Non-radiolabelled test subsatnce: 15 days daily followed on 16th day by single dose of radiolabelled test sustance. - Dose / conc.:
- 0.5 mg/kg bw/day (nominal)
- Remarks:
- Radiolabelled and non-radiolabelled test susbtances are given at this dose
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- Remarks:
- Radiolabelled test susbtance
- No. of animals per sex per dose / concentration:
- 5/sex
- Details on study design:
- - Dose selection rationale: The lower dose level (0.5 mg/kg) was selected as one that would produce no adverse effects, and, based on the specific activity of the radiotracer, was the lowest dose level that could be given if each rat was to receive at least 3 µCi of radioactivity. The higher dose level (25 mg/kg) was selected as a dose level that should inhibit cholinesterase activity and that might produce some clinical signs of cholinesterase depression. A dose level higher than 25 mg/kg was not used because of concern it might cause diarrhea and depress the absorption of orally administered test substance.
- Details on dosing and sampling:
- TOXICOKINETIC / PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: Urine, faeces, tissues (brain, gonads, heart, kidneys, liver, lungs and spleen), portions of the blood, bone, perirenal fat, skeletal muscle and skin.
- Time and frequency of sampling: Urine: 12-hr intervals for the first 72 hr. In-addition, urine was collected from female rats at 24-hr intervals between 72 and 144 hrs post-dosing. Feces were collected at 24-hr intervals for 72 hrs from the males and for 144 hrs from the females. The male and female rats were anesthetized with CO2 and exsanguinated 72 and 144 hr, respectively, after the 14C-labelled test substance was administered.
- Other: The charcoal and 14CO2 traps were changed 6, 12 and 24 hr after the 25 mg/kg dose was administered. Expired volatiles were not trapped following the single or multiple 0.5 mg/kg doses because no radioactivity was found in either the charcoal or 14CO2 traps following the 25 mg/kg dose
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: urine
- Time and frequency of sampling: The urine specimens used for the metabolite identification were taken from animals given the single 25 mg/kg oral dose. 12-24 Hr urine for males and males and 24-36 Hr urine for femlales only.
- From how many animals: Both males and female urine samples were pooled.
- Method type(s) for identification: HPLC and mass spectroscopy
- Limits of detection and quantification: Nor specified. - Statistics:
- Tissues in a group which did not contain sufficient radioactivity to quantify, the mean was calculated using half the limit of quantitation for those tissues which did not contain sufficient radioactivity to quantify. If the resulting mean was less than the limit of quantitation, the mean concentration was reported as being below the limit of quantitation. Slopes were calculated from the log transformed amounts of radioactivity excreted in the urine by the individual animals during the first 3 day post-dosing. Half-lives were obtained by dividing these slopes into the natural log of 2. These slopes and the cumulative amount of radioactivity excreted in the urine and feces were compared statistically using a 2-way analysis of variance with sex and dose as variables. Explicit comparisons were made using linear contrast statements in the analysis of variance procedure to test for differences between males and females at each dose level, between the single 0.5 and 25 mg/kg dose, and between the single and multiple 0.5 mg/kg dose.
- Type:
- absorption
- Results:
- 84% of the orally administered test substance was absorbed.
- Type:
- distribution
- Results:
- No differences were observed in the distribution of radioactivity recovered between the sexes or between rats given the single 25 and 0.5 mg/kg doses.
- Type:
- metabolism
- Results:
- Urinary metabolites were identified by mass spectrometry to be 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) and the glucuronide and tenatively the sulfate conjugate of 3,5,6-TCP.
- Type:
- excretion
- Results:
- Radioactivity was eliminated in the urine with a half-life of 8 to 9 hr the first 3 days following the 0.5 mg/kg dose and with half-lives of 12.4 hr in males and 23.2 hr in females given the 25 mg/kg dose.
- Details on absorption:
- Orally administered 14C-labelled test substance was rapidly and extensively absorbed by fasted rats. A half-life for absorption cannot be calculated from these data. However, it is apparent that chlorpyrifos was rapidly absorbed since over half of the 0.5 mg/kg oral doses was excreted in the urine within 12 hr. Based on the fraction of the dose found in the urine, it can also be concluded that at least 84% of the orally administered 14C-labelled test substance was absorbed.
- Details on distribution in tissues:
- The tissues and carcass from the rats given the 25 mg/kg dose after 72 and 144 h contained 0.2% of the administered radioactivity, while those from the rats given the single or repeated 0.5 mg/kg dose contained less than 0.01% of the administered radioactivity. Small amounts of radioactivity (~0.14 % dose/g) were found in the fat from the males at all dose levels, and in the liver of males and the ovaries and fat of females given the 25 mg/kg dose level. The other tissues did not contain sufficient radioactivity to reliably quantify, i.e., ~0.01% dose/g.
- Details on excretion:
- The principal route of excretion was the urine which contained between 83.9 and 91.7% of the dose. The feces contained from 5.5 to 11.5% of the administered radioactivity, and another 0.5 to 2.0% of the dose was found in the final cage wash. Very little radioactivity remained in the rats when they were sacrificed 72 hr (males) or 144 hr (females) post-dosing. Rats given multiple oral doses of 0.5 mg/kg excreted a larger fraction of the dose in the urine and less in the feces than the rats given the single 0.5 mg/kg oral dose. No differences were found in the disposition of radioactivity recovered following the single 0.5 and 25 mg/kg oral doses or between male and female rats at any dose level.
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- other: Elimination Half life
- Remarks:
- Radioactivity was eliminated in the urine with a half-life of 8 to 9 hr the first 3 days following the 0.5 mg/kg dose and with half-lives of 12.4 hr in males and 23.2 hr in females given the 25 mg/kg dose.
- Metabolites identified:
- yes
- Details on metabolites:
- Urinary metabolites were identified by mass spectrometry to be 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) and the glucuronide and tenatively the sulfate conjugate of 3,5,6-TCP.
- Conclusions:
- - Test substance was rapidly absorbed with over 84% of orally adminstered dose abosorbed.
- No differences were observed in the distribution of radioactivity recovered between the sexes or between rats given the single 25 and 0.5 mg/kg doses.
- Test substance was rapidly metabolized and eliminated in the urine as 3,5,6-TCP and the glucuronide and tentatively the sulfate conjugates of 3,5,6-TCP.
- Due to their rapid elimination, test substance and its metabolites have little potential to accumulate in the rat upon repeated administration. - Executive summary:
The study was conducted according to the EPA guideline 85-1 to evaluate the tissue distribution and metabolism of orally administered14C-labelled test substance in rats. Five rats/sex were given single oral doses of 0.5 or 25 mg 14C- labelled test substance/kg body weight, or 15 daily oral doses of 0.5 mg non-labelled test substance/kg followed on the 16thday by a single oral dose of 0.5 mg14C- labelled test substance/kg. Between 96.8 and 98.5% of the administered radioactivity was recovered. Most of the dose (83.9 to 91.7%) was excreted in the urine. Another 5.5 to 11.5% of the dose was eliminated in the feces. No radioactivity was found in the expired air. Only a small fraction of the administered radioactivity (≤0.2% of the dose) remained in the tissues and carcass of male and female rats terminated 72 and 144-hr post-dosing, respectively. A larger fraction of the repeated versus the single 0.5 mg/kg dose was excreted in the urine and less was eliminated in the feces; otherwise, the disposition of test substance was not altered by prior exposure to test substance. No differences were observed in the distribution of radioactivity recovered between the sexes or between rats given the single 25 and 0.5 mg/kg doses.
Radioactivity was eliminated in the urine with a half-life of 8 to 9-hr the first 3 days following the 0.5 mg/kg dose and with half-lives of 12.4-hr in males and 23.2-hr in females given the 25 mg/kg dose. The difference in elimination rates may have been secondary to differences in rates of absorption. No unchanged test substance was found in the urine. Urinary metabolites were identified by mass spectrometry to be 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) and the glucuronide and tentatively the sulfate conjugate of 3,5,6-TCP.
These data indicate that over 84% of the orally administered test substance was absorbed. Test substance was rapidly metabolized and eliminated in the urine as 3,5,6-TCP and conjugates of 3,5,6-TCP. Due to their rapid elimination, test substance and its metabolites have little potential to accumulate in the rat upon repeated administration.
Reference
Description of key information
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 84
Additional information
The study was conducted according to the EPA guideline 85-1 to evaluate the tissue distribution and metabolism of orally administered14C-labelled test substance in rats. Five rats/sex were given single oral doses of 0.5 or 25 mg 14C- labelled test substance/kg body weight, or 15 daily oral doses of 0.5 mg non-labelled test substance/kg followed on the 16thday by a single oral dose of 0.5 mg14C- labelled test substance/kg. Between 96.8 and 98.5% of the administered radioactivity was recovered. Most of the dose (83.9 to 91.7%) was excreted in the urine. Another 5.5 to 11.5% of the dose was eliminated in the feces. No radioactivity was found in the expired air. Only a small fraction of the administered radioactivity (≤0.2% of the dose) remained in the tissues and carcass of male and female rats terminated 72 and 144-hr post-dosing, respectively. A larger fraction of the repeated versus the single 0.5 mg/kg dose was excreted in the urine and less was eliminated in the feces; otherwise, the disposition of test substance was not altered by prior exposure to test substance. No differences were observed in the distribution of radioactivity recovered between the sexes or between rats given the single 25 and 0.5 mg/kg doses.
Radioactivity was eliminated in the urine with a half-life of 8 to 9-hr the first 3 days following the 0.5 mg/kg dose and with half-lives of 12.4-hr in males and 23.2-hr in females given the 25 mg/kg dose. The difference in elimination rates may have been secondary to differences in rates of absorption. No unchanged test substance was found in the urine. Urinary metabolites were identified by mass spectrometry to be 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) and the glucuronide and tentatively the sulfate conjugate of 3,5,6-TCP.
These data indicate that over 84% of the orally administered test substance was absorbed. Test substance was rapidly metabolized and eliminated in the urine as 3,5,6-TCP and conjugates of 3,5,6-TCP. Due to their rapid elimination, test substance and its metabolites have little potential to accumulate in the rat upon repeated administration.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.